Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL333251 | 0.75 | CYP2A6 (0.52) | CYP2A6 | |
| SCHEMBL23608159 | 0.74 | MAP4K4 (0.34) | — | |
| SCHEMBL762270 | 0.74 | PTK2 (0.50) | CYP2A6 | |
| SCHEMBL13815542 | 0.74 | — | — | |
| SCHEMBL13411813 | 0.73 | ADH5 (0.36) | — | |
| SCHEMBL703646 | 0.73 | LMNA (0.43) | — | |
| SCHEMBL19736786 | 0.71 | PRMT5 (0.39) | — | |
| SCHEMBL101638 | 0.71 | — | — | |
| SCHEMBL31357013 | 0.70 | CYP1A1 (0.46) | — | |
| SCHEMBL4950 | 0.70 | NR1H2 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11202784-B2 | Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency | CORCEPT THERAPEUTICS, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20200206243-A1 | USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS IN COMBINATION WITH GLUCOCORTICOIDS TO TREAT ADRENAL INSUFFICIENCY | CORCEPT THERAPEUTICS, INC. | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206243-A1 | USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS IN COMBINATION WITH GLUCOCORTICOIDS TO TREAT ADRENAL INSUFFICIENCY | CRH, MC2R, NR3C2 | XDH 929/4885ATM 3197/4885CYP2A6 917/4885 |
| US-11202784-B2 | Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency | NR3C2, MC2R, NR3C1 | XDH 604/4885ATM 2214/4885CYP2A6 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.